|drug1416||Infusion placebo Wiki||1.00|
|drug762||Convalescent anti-SARS-CoV-2 plasma Wiki||1.00|
|D011024||Pneumonia, Viral NIH||0.12|
|D045169||Severe Acute Respiratory Syndrome NIH||0.05|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
This is a Phase 3 randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of pacritinib in hospitalized patients with severe COVID-19 with or without cancer.
Description: The proportion is calculated as the number of patients who progress divided by the total number of patients in the ITT population.Measure: Proportion of patients who progress to IMV and/or ECMO or death during the 28 days following randomization Time: 28 days